Article
The Clinical Kinase Index: Prioritizing Understudied Kinases as Targets for the Treatment of Cancer
2020-02-14
Abstract excerpt
The approval of the first kinase inhibitor, Gleevec, in 2001, ushered in a paradigm shift for oncological treatment—the use of genomic data for targeted, efficacious therapies. Since then, over 48 additional small molecule kinase inhibitors have been approved, solidifying the case for kinases as a highly druggable and attractive target class. Despite the established role deregulated kinase activity plays in cancer...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7cdb89f1-646b-5307-93b2-c3c5dafc6dda
- DOI
- 10.1101/2020.02.14.943886
